AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03899649
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care treatment
Trial: NCT00993265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
Trial: NCT00047099
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00047099
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00869180
Drug: Matching Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
Trial: NCT03833479
Drug: TSR-042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
Trial: NCT02473445
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine Bitartrate Delayed-release capsules
Trial: NCT02171793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01200810
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00358488
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01246583
Drug: CP-690,550 Ointment 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CP-690,550 Ointment 1 twice daily for 4 weeks
Trial: NCT01246583
Drug: CP-690,550 Ointment 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CP-690,550 Ointment 2 twice daily for 4 weeks
Trial: NCT03673670
Drug: RPL554 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A PDE3/4 inhibitor
Trial: NCT00322283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-marched placebo, once per day, oral administration
Trial: NCT03673670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo solution
Trial: NCT02569814
Drug: Fimasartan/Amlodipine/Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02569814
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02922374
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
Trial: NCT01810185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01439282
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
Trial: NCT00350948
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 of 28 Day Cycle. 50 mg/m2
Trial: NCT02458755
Drug: High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg or Rosuvastatin 20mg
Trial: NCT01183559
Drug: 5 Fluorouracil (FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
Trial: NCT00515801
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules, single dose
Trial: NCT01556607
Drug: MDT-637
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled doses of MDT-637 over a 24 hour period at 3 visits
Trial: NCT01556607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01175018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
Trial: NCT04179734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaenous injection.
Trial: NCT00550758
Drug: Methachoine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
Trial: NCT00958334
Drug: Proellex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg daily (two 12.5 mg capsules)
Trial: NCT01936805
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
Trial: NCT04114292
Drug: Tauroursoursodeoxycholic acid, brand name Tudcabil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
Trial: NCT03435848
Drug: BST-236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 4 courses
Trial: NCT00818545
Drug: ER4017 (hydroxypropyltetrahydropyrantriol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream, 10%, each day during 3 months
Trial: NCT00818545
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03359356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 24 doses
Trial: NCT00151489
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00752635
Drug: Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03944447
Drug: Cannabis, Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
Trial: NCT01878292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose matched placebo tablets, once per day, oral administration.
Trial: NCT02347098
Drug: standard statin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Trial: NCT04640272
Drug: RBM-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT04114149
Drug: iv opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
Trial: NCT00276926
Drug: STI571
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03126747
Drug: BAY86-5300_YAZ-Flex
RxNorm normalized name: Ed Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
Trial: NCT00323882
Drug: MDX-010
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selected dose administered IV every 3 weeks
Trial: NCT01494532
Drug: placebo/L-dopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as adjunctive therapy with L-dopa
Trial: NCT01273051
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
Trial: NCT01230307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
Trial: NCT03714685
Drug: Firibastat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firibastat (QGC001) 500 mg
Trial: NCT00898807
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily for 9 weeks
Trial: NCT01647451
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two i.v. (intravenous) doses administered 6 weeks apart.
Trial: NCT00933673
Drug: L-asp, DXM, IFO, VP-16, DDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
Trial: NCT02456844
Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12.
Trial: NCT02456844
Drug: Methotrexate, Leucovorin and BMS-986142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10.
Trial: NCT00582673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01388660
Drug: Plavix/Astrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I \& II Day 1 (crossover manner)
Trial: NCT01527890
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous patient-controlled analgesia
Trial: NCT01499602
Drug: LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial release rate of 20µg Levonorgestrel per day for one year follow up.
Trial: NCT01626391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Trial: NCT00597480
Drug: rhGH norditropine simple Xx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)
Trial: NCT02740647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of 0.9% sodium chloride three times a day
Trial: NCT00056407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
Trial: NCT01571791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
Trial: NCT01571791
Drug: Ketorolac-Lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
Trial: NCT02411903
Drug: rosuvastatin and clopidogrel
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
Trial: NCT03391284
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL
Trial: NCT00530309
Drug: GSK716155 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
Trial: NCT00676676
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone atch delivering 300mcg daily for 8-weeks
Trial: NCT00751400
Drug: Naproxen Sodium ER (BAYH6689)
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumer use of Extended Release Naproxen Sodium
Trial: NCT00530309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will also receive placebo.
Trial: NCT03480321
Drug: PMR 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
Trial: NCT03480321
Drug: PMR 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
Trial: NCT02667054
Drug: RX0041 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic
Trial: NCT02316535
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adjuvant chemotherapy;
Trial: NCT03799250
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
Trial: NCT02667054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT02667054
Drug: RX0041 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic
Trial: NCT02191254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02037295
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills orally four times per day for 12 days
Trial: NCT03410173
Drug: Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03410173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00952497
Drug: Cisplatin, Capecitabine, Telatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
Trial: NCT01131676
Drug: Placebo BI 10773 high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical to BI 10773
Trial: NCT01131676
Drug: Placebo BI 10773 low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical to BI 10773
Trial: NCT03129321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00114049
Drug: GW406381
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00067028
Drug: Ara-C 0.75 g/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
Trial: NCT00067028
Drug: Ara-C 1 g/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
Trial: NCT01094769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose capsule taken once daily
Trial: NCT00649987
Drug: VoSpire® ER Tablets 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg, single dose fed
Trial: NCT01111851
Drug: MK0999
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)
Trial: NCT03070470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered orally)
Trial: NCT02281591
Drug: R-licarbazepine
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules containing 225 mg
Trial: NCT03982368
Drug: rhNGF 20 μg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
Trial: NCT03982368
Drug: rhNGF 20 μg/ml + vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon.
Trial: NCT02006342
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01472263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
Trial: NCT01823042
Drug: azathioprine+enteral nutrition
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01823042
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01333150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose of placebo
Trial: NCT00965874
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: serum salin
Trial: NCT03880266
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth
Trial: NCT00613145
Drug: Capecitabine and Sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
Trial: NCT00613145
Drug: Capecitabine and Sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
Trial: NCT01324258
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part1 and Part2
Trial: NCT03227900
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric infusion of water for injections
Trial: NCT01667029
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03161405
Drug: TAK-906 Maleate
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-906 capsule
Trial: NCT01074190
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Trial: NCT01074190
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Trial: NCT01074190
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.